Veracyte (VCYT) Operating Expenses (2012 - 2026)

Veracyte (VCYT) has 15 years of Operating Expenses data on file, last reported at $78.5 million in Q1 2026.

• Quarterly Operating Expenses rose 2.49% year-over-year to $78.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $306.7 million (up 5.21% YoY) and the FY2025 annual result came in at $304.8 million, up 8.07% from the prior year.
• Operating Expenses rose to $78.5 million in Q1 2026 per VCYT's latest filing, from $64.8 million in the prior quarter.
• The five-year high for Operating Expenses was $100.3 million in Q4 2023, with the low at -$35.1 million in Q4 2022.
• Average Operating Expenses over 5 years is $72.3 million, with a median of $76.6 million recorded in 2025.
• Year-over-year, Operating Expenses tumbled 144.1% in 2022 and jumped 385.43% in 2023.
• Veracyte's Operating Expenses stood at -$35.1 million in 2022, then jumped by 385.43% to $100.3 million in 2023, then decreased by 25.64% to $74.6 million in 2024, then slipped by 13.14% to $64.8 million in 2025, then rose by 21.2% to $78.5 million in 2026.
• Business Quant data shows VCYT's Operating Expenses at $78.5 million in Q1 2026, $64.8 million in Q4 2025, and $68.3 million in Q3 2025.